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Abstract
Background: Stroke prevention in atrial fibrillation (AF), most commonly with warfarin, requires maintenance of a
narrow therapeutic target (INR 2.0 to 3.0) and is often poorly controlled in practice. Poor patient-understanding
surrounding AF and its treatment may contribute to the patient’s willingness to adhere to recommendations.
Method: A theory-driven intervention, developed using patient interviews and focus groups, consisting of a one-off
group session (1–6 patients) utilising an “expert-patient” focussed DVD, educational booklet, self-monitoring diary
and worksheet, was compared in a randomised controlled trial (ISRCTN93952605) against usual care, with patient
postal follow-ups at 1, 2, 6, and 12-months. Ninety-seven warfarin-naïve AF patients were randomised to intervention
(n=46, mean age (SD) 72.0 (8.2), 67.4% men), or usual care (n=51, mean age (SD) 73.7 (8.1), 62.7% men), stratified
by age, sex, and recruitment centre. Primary endpoint was time within therapeutic range (TTR); secondary endpoints
included knowledge, quality of life, anxiety/depression, beliefs about medication, and illness perceptions.
Main Findings: Intervention patients had significantly higher TTR than usual care at 6-months (76.2% vs. 71.3%;
p=0.035); at 12-months these differences were not significant (76.0% vs. 70.0%; p=0.44). Knowledge increased
significantly across time (F (3, 47) = 6.4; p<0.01), but there were no differences between groups (F (1, 47) = 3.3; p =
0.07). At 6-months, knowledge scores predicted TTR (r=0.245; p=0.04). Patients’ scores on subscales representing
their perception of the general harm and overuse of medication, as well as the perceived necessity of their AF
specific medications predicted TTR at 6- and 12-months.
Conclusions: A theory-driven educational intervention significantly improves TTR in AF patients initiating warfarin
during the first 6-months. Adverse clinical outcomes may potentially be reduced by improving patients’ understanding
of the necessity of warfarin and reducing their perception of treatment harm. Improving education provision for AF
patients is essential to ensure efficacious and safe treatment.
The trial is registered with Current Controlled Trials, ISRCTN93952605, and details are available at
www.controlled-trials.com/ISRCTN93952605.
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Introduction
Oral anticoagulation (OAC) significantly reduces the risk of
stroke in atrial fibrillation (AF) patients [1]. Until recently the
mainstay of OAC therapy was vitamin K antagonists, most
commonly with warfarin. However, warfarin requires AF
patients to maintain a narrow therapeutic range (INR range 2.0
to 3.0). Analyses of a cohort of AF patients from the General
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Practice Research Database found that overall patients spent
63% of their time in therapeutic range (TTR) [2]. Patients that
spent at least 70% of their time in therapeutic range had a 79%
reduced risk of stroke compared to patients with ≤30% of time
in range [2].
Research suggests where patients have a greater
knowledge of warfarin therapy, INR values are more often
within the target therapeutic range [3]. However, AF patients
often exhibit limited knowledge of their condition and their
anticoagulant therapy [3–6]. A previous brief educational
intervention demonstrated a significant improvement in the
awareness of target therapeutic INR (p<0.0001) and factors
which may affect INR levels (p=0.005) when assessed six
weeks later [4]. An individual patient-data meta-analysis of self-
management trials demonstrated significant improvements in
TTR and a significant reduction in thromboembolic events with
self-monitoring but no difference in the risk of major bleeding or
death [7]. Whilst self-management improves anticoagulation
control, this may not be a feasible option for the majority of the
patients requiring anticoagulation, due to the training required
[8]. In addition, the associated costs of self-monitoring may
prevent wide-scale uptake [9], particularly with the arrival of
novel oral anticoagulants that do not require monitoring [9,10].
One study suggests that education alone may also have a
significant impact on time in therapeutic range (TTR) [11], but
the mechanisms by which education improves patient
adherence to the warfarin regimen are unclear. Evidence does
suggest that patients’ lack of knowledge surrounding their
condition and treatment presents a key barrier to uptake and
adherence [3,4]. Further, patients’ perceptions of their illness
suggest that AF patients may formulate inaccurate perceptions
[12], which may lead to intentional non-adherence to
medication.
Patient barriers to optimal OAC treatment are complex.
There are several reasons why patients may choose not to
take OAC or why they may not adhere to medication and
lifestyle recommendations. Factors include the presentation of
risk information and how this is communicated; particularly the
‘framing’ of the message as a positive or negative choice [13].
The evidence suggests the majority of AF patients are unaware
that they are at risk of stroke [14]. Patient’s lack of knowledge
surrounding their treatment and condition, coupled with the
potential burden of a complex regime may be barriers to
treatment uptake and adherence.
In this randomised controlled trial, we examined the impact
of a disease-specific theory-driven educational intervention on
TTR and other outcomes including patient knowledge, illness
perceptions, beliefs about medications, and perceived benefits
and burdens of warfarin, compared to patients with AF
receiving usual care alone.
Methods
Study design
All patients attending a specialist AF clinic or local
anticoagulation outpatient clinic, with documented AF, who
were warfarin-naïve (having never taken warfarin) and
accepting of OAC therapy were approached to participate in
the TREAT (TRial of an Educational intervention on patients’
knowledge of Atrial fibrillation and anticoagulant therapy, INR
control, and outcome of Treatment with warfarin) study. The
trial is registered with Current Controlled Trials,
ISRCTN93952605, and details are available at www.controlled-
trials.com/ISRCTN93952605. The protocol for this trial has
been previously published [15]. The protocol and supporting
CONSORT checklist are available as supporting information;
see Checklist S1 and Protocol S1. The TREAT intervention
was designed to provide intensive education for AF patients
newly prescribed warfarin and is based on psychological theory
and key clinical guidelines [16,17]. The purpose of the study
was to evaluate the use of a one-off theory driven educational
intervention on the primary endpoint of the proportion of time
spent within therapeutic INR range (TTR). Secondary
outcomes included patient knowledge, illness perceptions,
anxiety and depression, beliefs about medication, and health-
related quality of life.
Patients were randomised to receive either the intervention
or usual care. Patients were excluded from participation if they
were aged <18 years old, had any contraindication to warfarin,
had previously received warfarin, had valvular heart disease,
were cognitively impaired or had dementia, were unable to
speak or read English, or had any disease likely to cause their
death within the subsequent 12 months.
Materials and procedure
Patients received an information sheet detailing the study
and provided written informed consent. The research protocol
and amendments were approved by the Black Country Local
Ethics Research Committee. A telephone or face-to-face
interview permitted the collection of socio-demographic data
including: age, gender, occupational status, number of years in
education, postcode (for socio-economic status index) and
ethnicity. Further interrogation of hospital records allowed for
collection of baseline clinical measures (e.g. body mass index
(BMI), AF history, ECG, blood pressure, left ventricular
function, medication) and verification of socio-demographic
information. Patients completed a series of postal
questionnaires on five occasions: baseline, 1, 2, 6 and 12
months. The Beliefs about Medication Scale is an 18-item
questionnaire assessing patient’s specific beliefs about their
prescribed medication, including concerns and perceived
necessity of treatment, as well as their beliefs about medication
harm and overuse in general. Scores for each subscale are
summed and divided by the number of items, giving a score of
5 to 25 [18]. The Hospital Anxiety and Depression Scale, has
two separate subscales assessing anxiety and depression,
scores on each scale are summed with a score of ≥8 on either
sub-scale indicating a case [19]. The Brief Illness Perception
Questionnaire, based on the Common Sense Model, assesses
patients perceptions surrounding their illness (AF) including (i)
identity- symptoms patients associate with the illness and what
they attribute to the illness; (ii) consequences- expected
physical, social and economic implications; (iii) timeline - acute,
chronic or cyclical duration; (iv) causes- personal ideas about
causes; and (v) cure/control- the extent to which a patient
believes they will recover from or control their illness [20]. The
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Atrial Fibrillation Quality of Life (QoL) Questionnaire, an 18-
item health-related QoL scale, was used to assess
psychological, physical, sexual and global quality of life [21].
Values close to zero show a worse health state, while values
close to 100 indicate a better health state. The Patient
Knowledge Questionnaire (14 items) was previously designed
and piloted by our research group to assess patients’
knowledge of their condition, AF, and anticoagulant treatment
[4]. Nine items are scored to give a total knowledge score; the
remaining five items are qualitative and are coded to give
further qualitative insight into patients’ knowledge of AF and
OAC.
Endpoints
The primary endpoint is the proportion of time spent in
therapeutic INR range, INR2.0 to 3.0, at 6 and 12 months.
Every INR result, from baseline to the end of the study (12-
months), was recorded on an INR log sheet. INR readings
were undertaken by the anticoagulation service at each
hospital (independent of the study) to ensure the findings were
as ‘naturalistic’ as possible. The proportion of time each patient
spent in the therapeutic INR range (2.0 to 3.0) was calculated
by the method of linear interpolation (Rosendaal method) [22]
using data from month one to 12 (to allow attainment of the
correct dose of warfarin during the first four weeks) to give the
time spent within target therapeutic range (TTR). The following
secondary endpoints were also examined, patient’ knowledge,
beliefs about medication, anxiety and depression, illness
representations, and health-related QoL. Hospital admissions
and clinical outcomes (death, thromboembolism, stroke, major
bleeding, and myocardial infarction) during the first 12 months
were obtained from patients’ hospital records.
Randomisation and masking
A computer generated list stratified by (a) age (<70 and ≥70
years)/sex and (b) specialist AF clinic versus ‘general’
cardiology clinic, in blocks of four, randomised patients on an
individual basis to receive either ‘usual care’ or the intensive
educational intervention, in addition to ‘usual care’. The
randomisation schedule was designed by an independent trials
unit and the random allocation was obtained by the researcher
telephoning an associate researcher (not involved in the data
collection or data entry). A third researcher (not involved in the
data analysis or intervention delivery) matched patient
identification numbers with randomisation codes and checked
the completeness of follow-up questionnaires, and contacted
patients via telephone if any questions were not completed.
Patients who were unable to attend the intervention education
session within the specified time period (up to one month after
warfarin initiation) crossed over to the usual care arm (n=3).
The randomisation codes and data will be made available upon
request.
Intervention development and delivery
The intervention was designed utilising the ‘Necessity-
Concerns Framework’ to understand the key beliefs which
influence whether patients adhere to prescribed treatment or
not [23]. The model suggests that patients hold beliefs about
the necessity (specific-necessity) and concerns (specific-
concerns) surrounding prescribed medication. The model also
describes general beliefs about medication, assessing beliefs
that medicines are addictive and harmful (general-harm), and
that medicines are over-prescribed by doctors (general-
overuse). The Common Sense Model (CSM) also provided
guidance [20]. Utilising this model the intervention integrated
each of the five components that contribute to the formation of
a patient’s perception of their illness (AF). For example, to
ensure patients ‘understand the consequences’ the intervention
focussed on the physical, social and economic implications of
AF during the intervention.
TREAT intervention
Patients attended one group session [between 1–6 patients]
for one hour where they were shown a DVD of information
about the need for OAC, the risks and benefits associated with
OAC therapy, potential interactions with food, drugs, and
alcohol, and the importance of monitoring, and control of their
INR. The intervention was developed following discussions with
AF patient focus groups and patient interviews, and was
communicated in a variety of ways [i.e. by expert patients, a
cardiology consultant, other healthcare professional, and
examples of food/alcohol dietary components with educational
information as a voiceover script]. Patients were encouraged to
ask questions and complete a worksheet-based exercise
following each 10 minute DVD section.
Usual care
All patients received the standard ‘yellow booklet’ to identify
that they are taking OAC therapy. This book contains generic
information for all patients taking OAC (including deep vein
thrombosis, pulmonary embolism etc) and includes key safety
information including dietary advice (a brief paragraph
instructing patients not to miss meals and keep their diet
stable), medication (to inform GP/physician if they start a new
medication) and emergency contact information.
Three patients randomised to receive the intervention could
not attend the intervention within one month of warfarin
initiation. Two patients were ill during the month following
warfarin commencement and one patient could not be
contacted. Those patients that did not receive the intervention
were included in the usual care arm for the on-treatment
analyses.
Sample size calculation
Power for the primary endpoint was calculated based on
data from a secondary analysis of TTR from the ACTIVE-W
cohort by Connolly et al [24]. The power calculation assumes
that usual care patients would have a mean TTR of 58% with a
standard deviation (SD) of 7.5. We hypothesised a 6%
improvement in mean TTR in the intervention group with a
similar SD. In order for this improvement in TTR to be
statistically significant with a 1-beta power of 0.99 and
alpha=0.01, a sample size of 156 subjects in two equal groups
of 78 is needed, to allow for a 20% attrition rate.
For the secondary endpoint of improvement in knowledge
following the intervention, the sample size was calculated
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based on a study by Khan et al [11]. A sample size of 100
patients (50 in each group), allowing for a 20% attrition rate in
the completion of the questionnaires, will have at least 80%
power to detect an 18.5% increase in knowledge about the
condition and factors affecting INR control between baseline
and follow-up.
Statistical analysis
Data were analysed using IBM SPSS Statistics (Version
21.0). All tests were two tailed, where p-values ≤0.05 they were
considered statistically significant. Descriptive statistics are
presented for baseline demographic and clinical information.
Categorical variables were analysed using the chi-square
statistic and the Fisher exact test was used where there were
expected frequencies of less than five in any cell. Continuous
variables were compared using independent t-tests. Where
data were not normally distributed a Mann Whitney-U test was
used. All data were analysed by intention-to-treat. On-
treatment analyses are also provided for TTR. Three patients
who were randomised to the intervention group but could not
receive the intervention within one month of initiating warfarin
were included in the usual care group in the on-treatment
analysis. The primary endpoint, TTR, was determined by the
method of linear interpolation using the Rosendaal method
[22], using INR data from months one to 12. Differences in TTR
between the two groups were examined using the Mann
Whitney-U test and are reported as median and inter-quartile
range. Data for the secondary endpoints of patient’ knowledge,
beliefs about medication, anxiety and depression, illness
representations, and health-related QoL at the five time-points
(baseline, 1, 2, 6, and 12 months) are presented graphically to
illustrate the change in these variables over time between the
intervention and usual care groups. Assessment of the impact
of the intervention compared to usual care at 6 and 12 months
was undertaken using the change from baseline for each of the
secondary endpoints, with separate analyses for the 6 and 12
month time-points, using the Mann Whitney-U test and
employing a more conservative p-value (≤0.01) to adjust for a
Type I error due to multiple statistical comparisons. To
measure the change in variables across time (at five time
points including baseline, one, two, six and 12 month follow-
ups) and between groups (intervention and usual care groups)
for those who completed the questionnaires on all occasions
(n=29), data for each psychological outcome was entered into
separate two-factor mixed ANOVA analyses, where ‘group’ is
assumed fixed and ‘time-point’ is assumed random. Where the
assumptions of the test were violated (Mauchley’s test of
sphericity p<0.05), a more conservative p-value was reported
(Greenhouse-Geisser). Multiple regression analyses were used
to determine predictors of TTR.
Results
Ninety-seven patients participated in the study. Forty-six
patients were randomised to the intervention group and 51 to
usual care (see Figure 1). There were no significant differences
between the intervention and usual care groups on any
baseline demographic or clinical characteristics (see Table 1).
The mean (SD) age of the total cohort was 72.9 (8.2) years.
Almost half (48.4%) of the patients were aged 65-74 years old,
64.9% were male, and almost all (99.0%) were White British,
Irish or European. The median (IQR) years in education were
10 (9.5 to 12.0). The median (IQR) CHADS2 score for the total
cohort was 2 (1–3). There were no significant differences in
baseline prescribed medication. Three patients were unable to
attend the intervention within one month of commencing
warfarin and they received usual care only. There were no
significant differences in demographic or clinical variables
between the treatment groups in the on-treatment analyses
(data not shown).
Time within therapeutic range
In the intention-to-treat analysis, the intervention group spent
significantly more time in therapeutic INR range during the first
6 months of OAC initiation than patients receiving usual care
(76.2% vs. 71.3% respectively; p=0·035) (see Table 2).
Differences between the groups remained at the 12 month
follow-up (76.0% vs. 70.0%; p=0.44), but were non-significant
(see Table 2). At the 6 and 12 month follow-ups patients in the
usual care group spent more time with a sub-therapeutic INR
(INR<2·0) than patients in the intervention group but these
differences were not significant. Both the intervention and usual
care groups attended the anticoagulant clinic a similar number
of times at both the 6 and 12 month follow-ups. The results
were very similar for the on-treatment analyses however,
patients receiving usual care spent significantly more time with
sub-therapeutic INRs in the first 6 months than those receiving
the intervention (see Table 2).
Key baseline demographics, sex, age and years spent in
education were included in a multiple linear regression model
to predict TTR at 6 months. TTR was higher in women than in
men (74.5% (95% CI 57.7-97.3) vs. 72.3% (95% CI 59.3-86.8),
Figure 1.  CONSORT diagram illustrating recruitment
process and follow-up.  
doi: 10.1371/journal.pone.0074037.g001
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Table 1. Baseline demographics of the whole cohort and by
randomisation arm.
Demographic
characteristics
Mean (SD), n (%)
All participants
n=97
Intervention
n=46 Usual Care n=51p-value
Age, years 72.9 (8.2) 72.0 (8.2) 73.7 (8.1) 0.32
Age, years     
<65 14 (14.4) 6 (13.0) 8 (15.7)  
65-74 47 (48.5) 26 (56.5) 21 (41.2) 0.31
≥75 36 (37.1) 14 (30.4) 22 (43.1)  
Sex     
Males 63 (64.9) 31 (67.4) 32 (62.7) 0.79
Females 34 (35.1) 15 (32.6) 19 (37.3)  
Ethnicity     
White ‡ 96 (99.0) 46 (100.0) 50 (98.0) 1.00
Years in education
† 10 10 10 0.92
 (9.5-12.0) (9.75-12.0) (9.25-12.0)  
Socio-economic
status† 20.9 22.3 20.4 0.55
 (9.3-37.1) (9.5-38.1) (8.9-34.7)  
Body Mass Index
(kg/m2) 28.4 (5.4) 28.9 (5.6) 28.0 (5.2) 0.39
Type of AF     
Paroxysmal 30 (30.9) 13 (28.3) 17 (33.3)  
Persistent 22 (22.6) 11 (23.9) 11 (21.6) 0.37
Permanent 24 (24.7) 15 (32.6) 9 (17.6)  
Duration of known
AF in months † 3.0 (1.0-14.0) 3.0 (1.0-19.5) 2.0 (1.0-12.0) 0.87
Alcohol units per
week † 4.0 (0-12) 4.0 (0-14) 4.0 (0-10) 0.43
Smoking status     
Current smoker 4 (4) 3 (6.5) 1 (2.0)  
Ex-smoker 46 (46.5) 19 (41.3) 22 (43.1) 0.31
Non smoker 46 (46.5) 24 (52.2) 27 (52.9)  
CHADS2 risk
factors     
Congestive Heart
Disease/ LV
dysfunction
17 (17.5) 9 (19.6) 8 (15.7) 0.90
Hypertension 65 (67.0) 33 (71.7) 32 (62.7) 1.00
Age ≥75 36 (37.1) 14 (30.4) 22 (43.1) 0.31
Diabetes mellitus 15 (15.5) 7 (15.2) 8 (15.7) 0.95
Stroke 6 (6.2) 1 (2.2) 5 (9.8) 0.19
Transient
ischaemic attack 10 (10.3) 5 (10.9) 5 (9.8) 1.00
Total CHADS2
score† 2 (1-3) 2 (1-2) 2 (1-3) 0.28
Baseline
medication     
Calcium channel
blockers 23 (23.7) 9 (19.6) 14 (27.5) 0.47
Beta-blocker 36 (37.1) 20 (43.5) 16 (31.4) 0.34
Anti-platelet 11 (11.3) 6 (13.0) 5 (9.8) 0.88
ACE- inhibitor 40 (41.2) 23 (50.0) 17 (33.3) 0.16
Statin 34 (35.1) 17 (37.0) 17 (33.3) 0.92
respectively; z=-0.913, p=0.36), but differences were not
significant. There were no significant differences between age
Table 1 (continued).
Demographic
characteristics
Mean (SD), n (%)
All participants
n=97
Intervention
n=46 Usual Care n=51p-value
Digoxin 16 (16.5) 7 (15.2) 9 (17.6) 0.93
Diuretic 31 (32.0) 15 (32.6) 16 (31.4) 1.00
† Median (IQR); ‡ Only one patient in the study was not White (British/Irish/
European ACE, angiotensin converting enzyme; CHADS2, Congestive heart
failure/left ventricular dysfunction, Hypertension, Age ≥75 years, Diabetes mellitus
(1 point for presence of each), Stroke/Transient ischaemic attack (2 points); LV, left
ventricular;
doi: 10.1371/journal.pone.0074037.t001
Table 2. The proportion of time spent within therapeutic
range at 6 and 12 months stratified by treatment group.
 6 months 12 months
Intention-to-treat analyses
Median
(IQR) Intervention Usual care p-valueIntervention Usual care
p-
value
 (n=42) (n=49)  (n=37) (n=41)  
Overall
TTR 76.2 71.3 0.035 76.0 70.0 0.44
 (64.1-97.3) (51.2-84.7)  (60.5-85.0) (62.0-79.0)  
Proportion
of INR>3.0 0 (0-20.2) 8.9 (0-22.6) 0.17
12.0
(0.5-19.0)
10.0
(0-23.0) 0.91
Proportion
of INR<2.0 9.7 (0-28.9)
19.5
(2.6-33.2) 0.08
12.0
(5.0-22.5)
14.0
(6.0-24.0) 0.52
Mean (SD)
number of
INR visits
6.9 (2.3) 7.0 (2.9) 0.84 12.9 (4.0) 12.7 (3.8) 0.79
On-treatment analyses
Median
(IQR) Intervention Usual care p-valueIntervention Usual care
p-
value
 (n=39) (n=52)  (n=35) (n=43)  
Overall
TTR 82.5 68.9 0.009 76.0 69.0 0.21
 (66.7-97.6) (51.1-83.0)  (61.0-86.0) (60.0-78.0)  
Proportion
of INR>3.0 0 (0-20.0) 7.0 (0-22.0) 0.22
10.0
(0-20.0)
13.0
(0.22.0) 0.79
Proportion
of INR<2.0
8.45
(0-27.4)
19.8
(3.4-33.3) 0.021
12.0
(4.0-22.0)
15.0
(7.0-24.0) 0.26
Mean (SD)
number of
INR visits
6.7 (2.0) 7.2 (3.0) 0.35 12.5 (3.5) 13.0 (4.2) 0.57
INR = international normalised ratio, IQR = inter-quartile range; SD = standard
deviation; TTR = time in therapeutic range
INR data were not available on six (6.2%) patients at the 6 month follow-up and on
19 (19.6%) patients at the 12 month follow-up
doi: 10.1371/journal.pone.0074037.t002
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categories (<65, 65-74, ≥75 years; p=0.48), or years spent in
education (p=0.31). Years spent in education was the only
factor that predicted 12 month TTR (p=0.01).
Patient’s knowledge
Both groups of patients demonstrated good levels of
knowledge regarding AF at baseline, as they answered six out
of nine questions correctly on average. Knowledge scores
increased slightly in the intervention group over time, remaining
at a median score of seven at all subsequent time-points.
There were significant improvements in knowledge across time
(F(1,22) = 4.5; p<0.04), but not between groups.
A Spearman’s correlation coefficient revealed that patient
knowledge at baseline, one and two month follow-ups did not
predict TTR, whereas knowledge at the six month follow-up
weakly predicted overall TTR (r=0.245; p=0.04). There were no
significant correlations between the 12-month TTR and
knowledge scores at any time point.
Change in psychological measures from baseline to 6
and 12 months
The change from baseline to 6 months and baseline to 12
months was compared between groups for all psychological
variables (see Table S1). There was no significant change in
any of the psychological variables between groups at either 6
or 12 months. Therefore, exploratory analyses were conducted
to examine differences in the psychological variables over time
between the groups in patients who completed the
questionnaires at each time point to elucidate possible reasons
for the differences in TTR between groups at 6 and 12 months.
The number of patients completing questionnaires at 1, 2, 6
and 12 months was 72 (74.2%), 57 (58.8%), 61 (62.9%), and
53 (54.6%), respectively (see Table S2). However, only 29
(29.9%) patients completed ≥1 questionnaires at all time points
(some did not complete all questionnaires). The results are
reported below.
Illness Perceptions
There were significant differences in the patients’ perception
of the timeline of AF (whether patients perceive their AF
duration is acute, chronic or cyclical in duration) across time
(F(4,25) = 5.9; p<0.01), but no differences between groups.
Patients’ perceived treatment control (F(4,25) = 2.7; p=0.05),
emotional representation (F(4,26) = 3.1; p=0.04), and their
illness coherence scores changed significantly over time
(F(4,26) = 4.6; p<0.01), but there was no significant differences
between groups. IPQ factors did not predict TTR at 6 or 12
months.
Patients in the intervention group scored higher on illness
coherence, lower on emotional representation (how much their
illness affected them emotionally), and lower on illness concern
than the usual care group. However, none of the differences
between groups reached statistical significance (see Figure S2
and Table S3).
Quality of life
Patients in the intervention group scored lower at baseline on
all QoL subscales, suggesting worse QoL than in the usual
care group. QoL increased in the intervention group at the one
month follow-up. At all subsequent follow-ups there were no
significant differences in QoL scores between groups. There
were no significant differences in QoL between or within groups
(from baseline to 12 month follow-up) (see Figure S2).
Beliefs about medication
There were significant differences between groups in the
perception of the general harm of medication (F(1,28) = 4.4;
p<0.05); the intervention group viewed medication as less
harmful than the usual care group. There was also a significant
interaction between group and time (F(4,28) = 2.7; p=0.03), but
no significant changes across time in patients’ perception of
general harm (see Figure S3).
There was also a significant interaction between group and
time for patients’ perception of the general overuse of
medication (F(4,28) = 2.4; p=0.04). The usual care group
perceived medication as more overused by health care
professionals than the intervention group. No significant
differences between groups were evident in general overuse
(p=0.06), or changes in scores across time. There were no
significant differences between groups or across time in
patient’s scores for the specific necessity of medication
subscale. There was an interaction between time and group for
patients’ concerns regarding medication (F(4,27) = 2.9;
p=0.02); patients in the intervention group had fewer specific
concerns about medication at all time-points other than at the
12 month follow-up. There were no significant differences
between groups or across time for scores on the specific
concerns subscale.
A multiple linear regression model found that perceived
general harm of medication at 1 month was the only predictor
of TTR at 6 months (F(1,72) = 4.08; p=0.048). A negative
correlation (r=-0.241; p= 0.021) exists between general harm
scores and TTR; suggesting that as the perceived general
harm scores increased, TTR decreased. Baseline specific
necessity subscale scores predicted 12 month TTR (F(1,96) =
3.88; p=0.05). One month scores for specific necessity
(p=0.03), general harm (p=0.01) and general overuse (p=0.02)
also predicted 12 month TTR (F(3,72) = 3.4; p=0.02). General
harm (p=0.02) and general overuse (p=0.05) scores at the 6
month follow-up predicted 12 month TTR (F(2,61) = 3.2;
p=0.05).
Anxiety and Depression
At baseline, median anxiety scores for the total cohort were
just below the cut-off for clinical significance (score of ≥8; see
Table S3). At all subsequent follow-ups anxiety scores in both
groups increased significantly. A similar pattern was exhibited
with regard to depression. At baseline patients had relatively
low depression scores [median (IQR) 4.9 (2–8)], but these
scores increased significantly at each follow-up suggesting that
over half of the patients in both groups were depressed. The
prevalence of depression cases doubled from baseline to one
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month (25.5% to 55.6%), as did the prevalence of anxiety
(41.5% to 95.4%).
There was a significant increase in anxiety scores across
time (F(4,23) = 5.6; p<0.01), and significant differences
between the intervention and usual care groups (F(1,23) = 4.7;
p <0.05), but there was no significant interaction between time
and group. There was also a significant increase in depression
scores across time (F(4,23) = 14.4; p<0.01), but no significant
differences in depression between groups or interaction
between time and group (see Figure S4).
Adverse events
Only eight adverse events occurred during the 12 month
follow-up; seven in the usual care group (three ischaemic non-
fatal strokes, two minor bleeding episodes, one major bleeding
episode and one non-cardiac related death) and one event in
the intervention group (peripheral embolism).
Discussion
In this randomised trial, the TREAT intervention significantly
improved patients’ warfarin control compared to usual care,
evidenced by significantly more time spent in the therapeutic
INR range at the 6 month follow-up. Patients in the intervention
group had better TTR at 12 months than those receiving usual
care only but these differences were not significant. This
suggests greater adherence to medication and lifestyle
recommendations in those patients receiving the TREAT
intervention.
Two recent systematic reviews and meta-analyses [25,26],
one examining supplemental education for patients taking OAC
(for any indication) [25], and the other investigating educational
and behavioural interventions on OAC therapy exclusively in
AF patients [26], found that such interventions did not
significantly improve TTR. However, both concluded that this
was likely dependent on the considerable clinical and
methodological heterogeneity of included studies and poorly
designed interventions (which did not employ intensive
education or behaviour change interventions designed to affect
psychological outcomes and improve treatment adherence)
rather than the lack of benefit of educational interventions per
se on outcomes, and called for larger randomised trials with
longer follow-up, in patients initiating OAC therapy, with clearly
defined educational interventions [25,26].
To our knowledge only one randomised controlled trial has
explored the impact of education alone on adherence in AF
patients, and this trial did not exclusively target patients who
were newly diagnosed with AF or who were warfarin naïve [11].
Further, Khan and colleagues did not account for psychological
barriers to adherence, such as inaccurate perceptions of illness
(including a poor understanding of the cause, consequences
and timeframe of AF) or beliefs about medication. By
increasing the provision of information to patients to help them
to formulate accurate beliefs and perceptions surrounding AF
and warfarin, patients maybe more able and willing to adhere,
in the long-term, to treatment recommendations through better
understanding of the condition and its’ treatment. The clinical
implications of these findings are important as the effectiveness
of oral anticoagulation treatment with warfarin is often
undermined by low levels of adherence [27–30]. Maintaining
the therapeutic INR range of 2·0 to 3·0 is imperative for stroke
risk reduction and to reduce the risk of treatment-associated
bleeding complications [2,27,31–33]. Evidence suggests that
warfarin treatment offers no or limited clinical benefit (reduced
stroke and mortality) unless a patient can maintain their
therapeutic range for more than 71% of the time [2]; a target
achieved by those in the intervention group at both 6 and 12
months. Thus, the use of a one-off theory-driven intervention
could help to ensure that patients starting warfarin would
establish and maintain ‘good’ INR control and therefore
achieve the desired treatment benefit. Improvements to usual
care TTR over time are likely caused by their experiences of
the warfarin regime and even minor bleeding episodes.
Improving TTR in the first six months of treatment is
essential, as it is this period of time where patients have the
most unstable INR control and are most likely to discontinue
therapy [2]. The non-significant difference in TTR between the
intervention and usual care groups at 12-months does not
necessarily mean that the educational intervention does not
offer added benefit over usual care (as shown at 6-months), it
may simply mean that the educational intervention needs to be
repeated after 6-months because either the information and the
behaviour change techniques are not retained in the longer
term by some patients or more likely, some patients need these
to be reinforced. The TREAT intervention is not simply about
giving information it also gives patients a framework to make
the necessary behavioural changes and strategies to maintain
these over time. Therefore, a further ‘top-up’ of the intervention
may be warranted six months after receiving the initial
intervention, which may help to maintain the significantly
improved levels of adherence. Indeed, a European-wide study
of medication adherence identified that persistence with
therapy is enhanced by interventions comprising education
together with motivational and performance-based feedback
and that such interventions may need to be repeated at
intervals to support and reinforce behavioural change [34].
Patients’ knowledge scores at six months predicted TTR.
This indicates that where patients’ knowledge regarding their
illness and their treatment is sustained, patients are more likely
to remain within target therapeutic range. The relationship
between knowledge and adherence is unclear; however, it is
possible that improving patient knowledge could reduce
intentional and unintentional non-adherence [35]. Non-
adherence is intentional when patients make a decision not to
take their treatment as a result of their personal motivations or
beliefs. Where these beliefs are inaccurate, or they perceive
the barriers as too great, they are unlikely to adhere. Equally,
improved knowledge of specific questions (e.g. ‘what should I
do if I miss a dose of warfarin?’) could reduce unintentional
non-adherence; which refers to an individual’s skills or ability to
take their medications correctly (e.g. problems with
remembering to take tablets). Evidence suggests that patients
often report either or both types of non-adherence, with
occasional overlap between the two concepts (e.g. where
patients perceive medications as being unnecessary, they
maybe more likely to forget to take it) [35,36]. Previous studies
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have also highlighted the link between knowledge and INR
control [3,11].
There is a paucity of trialled theory-based interventions,
despite the overwhelming evidence and guidelines to support
their use [17,35,37]. For example, previous evidence has
highlighted the link between patients’ beliefs about their
medication and adherence but few interventions have
addressed this potential link. By targeting those beliefs, and
potentially improving adherence to medication, we may
subsequently improve clinical outcomes.
Where patients view their medication as harmful, they are
less likely to adhere [23,35,38]. This has been related to
perceived ‘toxicity’ of medications, and patients’ views
surrounding the impact of side effects in the short- and long-
term [35]. Indeed, the present study found significant
differences between the intervention and usual care group in
their perception of medication harm in general and a significant
interaction between general harm scores across time and
between groups. It seems an obvious assumption that
perceiving medications as harmful represents a barrier to
adherence, and yet this is rarely considered in intervention
design. Patients must undergo a personal risk evaluation when
choosing to start a new medication, perhaps taking into
consideration potential side effects (i.e. bleeding and bruising),
perceived toxicity/potency of medication and risk reduction
associated with warfarin [35]. This procedure is reliant on their
ability to balance the risks associated with their treatment with
those associated with their condition (i.e. stroke risks
associated with AF vs. bleeding risks associated with warfarin).
Many AF patients may have preconceived ideas about how
harmful warfarin is for example patients are more willing to take
warfarin when they are blinded to the name of the treatment
[39,40], highlighting the negative connotations associated with
warfarin (e.g., ‘rat-poison). It is important that patients do not
rely on inaccurate perceptions of harm, and that their risk
evaluation draws upon reliable knowledge. The TREAT
findings suggest that by reducing patients’ perception of harm,
it may be possible to increase adherence levels. The inclusion
of ‘expert’ patient narratives discussing their own experiences
of bleeding and bruising in the DVD allowed the intervention
group to assimilate this risk information into their own belief
system.
There were also significant differences between the
intervention and usual care groups’ perception of specific
concern about their AF medication. Previous evidence
suggests that those patients scoring higher on the specific
concern subscale are less likely to adhere to medication
[36,38,41]. This could provide some explanation as to why the
intervention group spent more time in therapeutic range,
although results do not suggest a causal link between specific
concerns and TTR.
Using the sub-scales of the beliefs about medication
questionnaire, it is possible to calculate a necessity-concerns
differential score. This represents the difference between
patients’ concerns about their AF medication and their
perception of its necessity and there were significant
differences across time and between groups. The intervention
group scored higher, suggesting these patients perceived the
necessity for warfarin as more important than their concerns
about taking it. Baseline differential scores significantly
correlated with TTR at six months, suggesting those patients
with lower scores on specific concern, and higher scores on
specific necessity (thus higher differential scores), also spent
more time in the therapeutic range. This supports previous
evidence with depressed patients taking selective serotonin
reuptake inhibitors, whereby high necessity and low concern
scores surrounding their anti-depressants were associated with
greater self-reported adherence [42].
Limitations
The majority of the TREAT participants were of white
ethnicity, which does not reflect the multi-ethnic community of
the West Midlands; but it does reflect the disease prevalence,
as AF is predominantly seen in white populations [43].
However, the intervention is applicable to all ethnic groups and
could be easily adapted into a range of languages, and to be
culturally sensitive (e.g. including specific dietary
requirements). The recruitment target was 78 patients in each
group (allowing for a 20% attrition rate over time) however, 234
(36.2%) eligible patients declined to participate primarily due to
the questionnaire burden; the decline rate was higher than we
had anticipated resulting in only 97 patients being recruited.
This trial may be limited somewhat by its small sample size
however, other similar trials have also demonstrated significant
differences in outcomes between groups with comparable
samples [11], although it is possible that some relationships
between factors studied remained undetected, due to a lack of
statistical power. In addition, given the questionnaire burden, a
large proportion of the sample failed to complete all
questionnaires at every time point which resulted in the
analyses of the psychological variables over time to elucidate
factors which might explain the significant difference in TTR at
6 months between groups being exploratory, as they could only
be undertaken in those who completed the questionnaires at
every time point. Although the number of patients completing
questionnaires at each time point fell over time, the proportion
was similar in the intervention and usual care arms over the
first six months. However, it was significantly lower in the
intervention group at 12 months therefore, since the
exploratory analyses only included those who had completed
the 12 month set, these results may not be representative of
the whole cohort.
Whilst novel OAC provides an alternative treatment, without
the inconvenience of INR monitoring and lifestyle changes,
there is currently some resistance to prescribing them due in
part to the cost and the lack of ‘real-life’ efficacy and safety
data, compared to warfarin. Therefore, warfarin is likely to
remain as a treatment option for stroke prevention in AF. In
addition, patient preferences for OAC treatment are also
important in facilitating a shared decision-making process and
many patients may still choose warfarin or prefer to remain on
warfarin, or be unable or unwilling to take the new OACs [6].
Clinicians are often reluctant to prescribe warfarin due to
patients’ lack of knowledge surrounding OAC and patients’
management of factors that might affect INR control [4]. The
benefit of this intervention in terms of improvement in TTR may
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help to alleviate some of these fears, increase uptake and
adherence, and translate into fewer adverse outcomes. Thus a
one-off intensive intervention package provides a cost-effective
alternative in improving INR control, and this intervention could
be adapted for use with novel oral anticoagulant drugs.
Conclusion
The TREAT intervention provides a simple one-off
behavioural education session, which significantly improves
adherence to warfarin as evidenced by greater TTR compared
to usual care. Improving patient understanding surrounding AF,
treatment necessity and stroke risk reduction, facilitates
informed decisions about the management of their condition
and treatment and can also make a significant difference to
long-term adherence. The intervention’s ability to improve
adherence highlights the importance of AF patients’
perceptions of the necessity of their treatment and clinical
outcomes. Whilst novel oral anticoagulants are likely to
become more widely available, removing the need for INR
monitoring, warfarin will still remain as a widely used treatment
option. Educating patients remains important regardless of the
type of anticoagulation (VKA or novel OAC) to ensure patients
are managing their treatment appropriately.
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